Gapping up
In reaction to strong earnings/guidance: EHTH +26.7%, IMH +24.1%, SIVB +22.4%, GIMO +17.6%, AMZN +12.1%, JNPR +8.1%, HMHC +6.8%, QDEL +6.2%, ALGN +5.3%, CPHD +5.1%, QLIK +4.9%, DGII +4.8%, MSFT +4.5%, SHOO +4.3%, SBUX +3.9%, GOOG +3.3%, BAS +3.3%, NEM +3.1%, HA +3%, FLIR +2.8%, AAN +2.6%, ACTG +2.5%, BGG +2%, VTR +1.3%,DTE +1.2%, STT +1%, COG +1%
M&A news: LOOK +23.1% (Looksmart announces spin-off and definitive merger agreement with Pyxis)
Select EU financial related names showing strength: NBG +5.1%, HSBC +3.6%, BCS +2.9%, LYG +0.9%
Select ometals/mining stocks showing strength: CLF +2.7%, BHP +2.6%, RIO +2.3%, MT +2.3%, VALE +2.2%, FCX +1.2%
Other news: HKTV +17.3% (discloses updated court ruling relating to the company's application for a domestic free television programme service licence ), INNL +12.9% prices its follow on offering at $9/ADS share), MCP +6.6% (cont strength after yday's news that China will end taxes on aluminum-alloy & rare earth ores), DRNA +4% ( confirms that the FDA grants Orphan Drug Designation for DCR-PH1 to treat primary hyperoxaluria type 1 ), CIDM +3.1% prices its $64 mln private offering of 5.5% senior convertible notes due 2035), DNKN +3% (Dunkin' Brands to replace Riverbed in S&P 400 ), BIOD +2.4% (Rock Springs Capital Management disclosed a 6.99% passive stake in 13G filing), WD +2.3% (WD to replace ENTR in the S&P SmallCap 600), AGEN+1.9% (announces the final results from the Phase 3 study of GlaxoSmithKline's (GSK) candidate, RTS,S, demonstrated a statistically significant reduction against malaria in children), CTSO +1.9% (issues letter to shareholders; believe potential opportunities for 'significant future growth' greatly outweigh near-term concerns), BMY +1.5% (confirms positive CHMP opinion in the European Union for Opdivo), TWC +1.4% (RBC discusses possibility for another attempt by CHTR to acquire TWC; sees TWC's take-out price of $151 in such a scenario), VTR +1.3% (Ventas announces filing of form 10 Registration Statement for spin-off of post-acute / skilled nursing facility portfolio), NGL +1.1% (announces an increase in its quarterly distribution to $0.625/unit from $0.6175/unit), MRK +0.9% (Phase 3 C-EDGE program evaluating Grazoprevir/Elbasvir shows high sustained virologic responses across broad range of patients with chronic Hepatitis C virus infection), RF +0.8% ( increases quarterly common stock dividend to $0.06 per share and announces $875 million common stock repurchase program)
Analyst comments: MAT +4% (upgraded to Buy from Neutral at Goldman), CSCO +1.7% (added to Conviction Buy List at Goldman), CVC +1% (upgraded to Hold from Sell at Brean Capital)
In reaction to strong earnings/guidance: EHTH +26.7%, IMH +24.1%, SIVB +22.4%, GIMO +17.6%, AMZN +12.1%, JNPR +8.1%, HMHC +6.8%, QDEL +6.2%, ALGN +5.3%, CPHD +5.1%, QLIK +4.9%, DGII +4.8%, MSFT +4.5%, SHOO +4.3%, SBUX +3.9%, GOOG +3.3%, BAS +3.3%, NEM +3.1%, HA +3%, FLIR +2.8%, AAN +2.6%, ACTG +2.5%, BGG +2%, VTR +1.3%,DTE +1.2%, STT +1%, COG +1%
M&A news: LOOK +23.1% (Looksmart announces spin-off and definitive merger agreement with Pyxis)
Select EU financial related names showing strength: NBG +5.1%, HSBC +3.6%, BCS +2.9%, LYG +0.9%
Select ometals/mining stocks showing strength: CLF +2.7%, BHP +2.6%, RIO +2.3%, MT +2.3%, VALE +2.2%, FCX +1.2%
Other news: HKTV +17.3% (discloses updated court ruling relating to the company's application for a domestic free television programme service licence ), INNL +12.9% prices its follow on offering at $9/ADS share), MCP +6.6% (cont strength after yday's news that China will end taxes on aluminum-alloy & rare earth ores), DRNA +4% ( confirms that the FDA grants Orphan Drug Designation for DCR-PH1 to treat primary hyperoxaluria type 1 ), CIDM +3.1% prices its $64 mln private offering of 5.5% senior convertible notes due 2035), DNKN +3% (Dunkin' Brands to replace Riverbed in S&P 400 ), BIOD +2.4% (Rock Springs Capital Management disclosed a 6.99% passive stake in 13G filing), WD +2.3% (WD to replace ENTR in the S&P SmallCap 600), AGEN+1.9% (announces the final results from the Phase 3 study of GlaxoSmithKline's (GSK) candidate, RTS,S, demonstrated a statistically significant reduction against malaria in children), CTSO +1.9% (issues letter to shareholders; believe potential opportunities for 'significant future growth' greatly outweigh near-term concerns), BMY +1.5% (confirms positive CHMP opinion in the European Union for Opdivo), TWC +1.4% (RBC discusses possibility for another attempt by CHTR to acquire TWC; sees TWC's take-out price of $151 in such a scenario), VTR +1.3% (Ventas announces filing of form 10 Registration Statement for spin-off of post-acute / skilled nursing facility portfolio), NGL +1.1% (announces an increase in its quarterly distribution to $0.625/unit from $0.6175/unit), MRK +0.9% (Phase 3 C-EDGE program evaluating Grazoprevir/Elbasvir shows high sustained virologic responses across broad range of patients with chronic Hepatitis C virus infection), RF +0.8% ( increases quarterly common stock dividend to $0.06 per share and announces $875 million common stock repurchase program)
Analyst comments: MAT +4% (upgraded to Buy from Neutral at Goldman), CSCO +1.7% (added to Conviction Buy List at Goldman), CVC +1% (upgraded to Hold from Sell at Brean Capital)